Table 2 Impact of different therapeutic agents on Lp(a) levels and therapeutic roles for breast cancer
Therapeutic agent | Population type | Change in Lp(a) | Therapeutic roles for breast cancer |
|---|---|---|---|
Hormone replacement therapy | Post-menopausal women | -25% [63] | Not applicable |
Statins | Randomized population | 8.5–19.6% [64] | Delays the progression and prevents its recurrence |
Aspirin | Randomized population | Inconclusive results but can reduce the CVD risk [65] | Reduces the incidence and the chance of cancer metastasis |
PCSK9 inhibitors | Patients with high baseline Lp(a) | -24.5–29.5% (more significant in those with baseline Lp(a) of ≤ 125 nmol/l) [66] | Not applicable |
Lipoprotein apheresis | Patients with high baseline Lp(a) | -60–70% [67] | Not applicable |
Mipomersen | Patients with high baseline Lp(a) | -26.4% [68] | Not applicable |
AKCEA-APO(a)-LRX | Patients with baseline Lp(a) > 60 mg per deciliter | -50–80% [69] | Not applicable |
IONIS-APO(a) | Patients with baseline Lp(a) ≥ 75 nmol/L | -60–80% [70] | Not applicable |
SLN360 | Patients with baseline Lp(a) ≥ 150 nmol/L | Dose dependent ( -10–98%) [71] | Not applicable |
Olpasiran(AMG890) | Patients with high baseline Lp(a) | -70–97% [72] | Not applicable |
Inclisiran | Patients with high baseline Lp(a) | Inconclusive results | Not applicable |